pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase

@inproceedings{An2017pSILACMS,
  title={pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase},
  author={Jian An and Charles M Ponthier and Ragna Sack and Jan Seebacher and Michael B. Stadler and Katherine A Donovan and Eric S Fischer},
  booktitle={Nature communications},
  year={2017}
}
Thalidomide and its derivatives lenalidomide and pomalidomide (IMiDs) are effective treatments of haematologic malignancies. It was shown that IMiDs impart gain-of-function properties to the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) ubiquitin ligase that enable binding, ubiquitination and degradation of key therapeutic targets such as IKZF1, IKZF3 and CSNK1A1. While these substrates have been implicated as efficacy targets in multiple myeloma (MM) and 5q deletion associated myelodysplastic syndrome (del… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
4 Citations
53 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 53 references

Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation

  • Winter, E G.
  • Science 348,
  • 2015

Similar Papers

Loading similar papers…